Scarica l'app Stockscreener
19.39
10.42%
1.83
Dopo l'orario di chiusura:
19.39
Precedente Chiudi:
$17.56
Aprire:
$17.89
Volume 24 ore:
366.50K
Relative Volume:
2.07
Capitalizzazione di mercato:
$169.75M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-969.50
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
+10.11%
1M Prestazione:
-0.26%
6M Prestazione:
+35.96%
1 anno Prestazione:
-12.66%
Intervallo 1D:
$17.10
$19.85
Intervallo di 1 settimana:
$15.81
$19.85
Portata 52W:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Confronta MCRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.39 | 153.73M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Cuts Jobs To Fund Next Microbiome Bet As Cash Runs Low - insights.citeline.com
MCRB: Analyst John Newman Raises Price Target to $22 | MCRB Stoc - GuruFocus
Canaccord Genuity raises Seres Therapeutics stock price target to $22 on FDA hopes - Investing.com
Seres Therapeutics price target raised to $22 from $14 at Canaccord - TipRanks
Seres Therapeutics (MCRB) Plans Workforce Reduction to Extend Ca - GuruFocus
Seres Therapeutics (MCRB) Advances with FDA Feedback on SER-155 Study - GuruFocus
Seres Therapeutics advances SER-155 protocol after FDA feedback By Investing.com - Investing.com Australia
Seres Therapeutics advances SER-155 protocol after FDA feedback - Investing.com
Seres Therapeutics to Cut Staff by 25%, Extend Cash Runway - MarketScreener
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - The Manila Times
Seres Therapeutics Advances SER-155 Phase 2 Study Protocol and Initiates Workforce Reduction to Extend Cash Runway - Quiver Quantitative
Seres Therapeutics announces further constructive feedback from FDA on SER-155 Phase 2 study protocol and implements cost reduction actions to extend cash runway - MarketScreener
25% Workforce Cut: Seres Therapeutics Extends Cash Runway While Advancing Breakthrough Blood Infection Drug - Stock Titan
Seres Therapeutics Inc. stock retracement – recovery analysisMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
What indicators show strength in Seres Therapeutics Inc.July 2025 Decliners & Consistent Growth Equity Picks - newser.com
How high can Seres Therapeutics Inc. stock goMarket Performance Recap & Consistent Profit Alerts - newser.com
Developing predictive dashboards with Seres Therapeutics Inc. dataTrade Entry Summary & Weekly High Momentum Picks - newser.com
Combining machine learning predictions for Seres Therapeutics Inc.Buy Signal & Free Accurate Trade Setup Notifications - newser.com
What to expect from Seres Therapeutics Inc. in the next 30 daysJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Technical analysis overview for Seres Therapeutics Inc. stockQuarterly Market Summary & Daily Price Action Insights - newser.com
Is this a good reentry point in Seres Therapeutics Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
What earnings revisions data tells us about Seres Therapeutics Inc.Oil Prices & Daily Momentum Trading Reports - newser.com
Revenue Check: What are Flag Ship Acquisition Corporations technical support levelsWeekly Stock Recap & Precise Swing Trade Alerts - khodrobank.com
Aug EndMonth: Is Seres Therapeutics Inc impacted by rising rates2025 Breakouts & Breakdowns & AI Forecast Swing Trade Picks - khodrobank.com
Seres Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:MCRB - Benzinga
Candlestick signals on Seres Therapeutics Inc. stock todayJuly 2025 Price Swings & Verified Entry Point Signals - newser.com
Measuring Seres Therapeutics Inc.’s beta against major indicesPortfolio Profit Report & Weekly Top Performers Watchlists - newser.com
Nasdaq Moves: Can Seres Therapeutics Inc. be the next market leaderJuly 2025 Review & Stock Market Timing Techniques - خودرو بانک
Can swing trading help recover from Seres Therapeutics Inc. lossesDollar Strength & Safe Capital Growth Trade Ideas - newser.com
Risk Analysis: What’s next for Seres Therapeutics Inc. stockWeekly Stock Summary & Verified Trade Idea Suggestions - خودرو بانک
Aug Closing: What are Seres Therapeutics Inc.’s earnings expectationsWeekly Trade Report & Safe Capital Growth Tips - خودرو بانک
Seres Therapeutics Inc. recovery potential after sell offJuly 2025 Spike Watch & Accurate Intraday Trade Tips - newser.com
Understanding Seres Therapeutics Inc.’s price movementEarnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Short Covering: Why is A0ULJS stock going upPrice Action & Low Risk Entry Point Guides - khodrobank.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Volume & Smart Allocation Stock Reports - newser.com
Intraday pattern recognizer results for Seres Therapeutics Inc.Analyst Downgrade & Weekly Top Gainers Alerts - newser.com
How to monitor Seres Therapeutics Inc. with trend dashboardsJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Using data tools to time your Seres Therapeutics Inc. exitMarket Performance Report & Daily Market Momentum Tracking - newser.com
Seres Therapeutics soars on report of takeover offer - MSN
Aug Gainers: Is Granite Construction Incorporated showing insider buyingEntry Point & Growth Oriented Trade Recommendations - خودرو بانک
Momentum Shift: Can Seres Therapeutics Inc outperform under higher oil pricesInflation Watch & Technical Pattern Recognition Alerts - خودرو بانک
VIX Spike: Is Seres Therapeutics Inc. backed by strong institutional buying2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Buyout Rumor: What is Janux Therapeutics Inc.’s valuation compared to sectorQuarterly Profit Report & Accurate Intraday Trading Signals - خودرو بانک
What data driven models say about Seres Therapeutics Inc.’s futureGold Moves & Smart Swing Trading Techniques - newser.com
Chart Watch: Is WINA subject to activist investor interestQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - خودرو بانک
Breakout Watch: Is Seres Therapeutics Inc. backed by strong institutional buyingJuly 2025 Recap & Safe Capital Growth Tips - خودرو بانک
Analyzing net buyer seller activity in Seres Therapeutics Inc.2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
Fund Flows: Whats Seres Therapeutics Incs historical returnJuly 2025 Snapshot & Pattern Based Trade Signal System - خودرو بانک
Aug Movers: Is Cactus Inc stock heavily shortedJuly 2025 Earnings & Short-Term Swing Trade Alerts - خودرو بانک
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):